WWW.DISSERTATION.XLIBX.INFO
FREE ELECTRONIC LIBRARY - Dissertations, online materials
 
<< HOME
CONTACTS



Pages:   || 2 |

«Package leaflet: Information for the patient Cosentyx® 150 mg solution for injection in pre-filled pen Secukinumab This medicine is subject to ...»

-- [ Page 1 ] --

Package leaflet: Information for the patient

Cosentyx® 150 mg solution for injection in pre-filled pen

Secukinumab

This medicine is subject to additional monitoring. This will allow quick identification of new safety

information. You can help by reporting any side effects you may get. See the end of section 4 for how to

report side effects.

Read all of this leaflet carefully before you start using this medicine because it contains important

information for you.

- Keep this leaflet. You may need to read it again.

- If you have any further questions, ask your doctor, pharmacist or nurse.

- This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours.

- If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. See section 4.

What is in this leaflet

1. What Cosentyx is and what it is used for

2. What you need to know before you use Cosentyx

3. How to use Cosentyx

4. Possible side effects

5. How to store Cosentyx

6. Contents of the pack and other information

1. What Cosentyx is and what it is used for Cosentyx contains the active substance secukinumab. Secukinumab is a monoclonal antibody. Monoclonal antibodies are proteins that recognise and bind specifically to certain proteins in the body.

Cosentyx belongs to a group of medicines called interleukin (IL) inhibitors. This medicine works by neutralising the activity of a protein called IL-17A, which is present at increased levels in diseases such as psoriasis, psoriatic arthritis and ankylosing spondylitis.

Cosentyx is used for the treatment of the following inflammatory diseases:

 Plaque psoriasis  Psoriatic arthritis  Ankylosing spondylitis Plaque psoriasis Cosentyx is used to treat a skin condition called “plaque psoriasis”, which causes inflammation affecting the skin. Cosentyx reduces the inflammation and other symptoms of the disease. Cosentyx is used in adults with moderate to severe plaque psoriasis.

Using Cosentyx in plaque psoriasis will benefit you by leading to improvements of skin clearance and reducing your symptoms such as scaling, itching and pain.

Psoriatic arthritis Cosentyx is used to treat a condition called “psoriatic arthritis”. The condition is an inflammatory disease of the joints, often accompanied by psoriasis. If you have active psoriatic arthritis you will first be given other medicines. If you do not respond well enough to these medicines, you will be given Cosentyx to reduce the signs and symptoms of active psoriatic arthritis, improve physical function and slow down the damage to the cartilage and bone of the joints involved in the disease.

Cosentyx is used in adults with active psoriatic arthritis and canbe used alone or with another medicine called methotrexate.

Using Cosentyx in psoriatic arthritis will benefit you by reducing the signs and symptoms of the disease, slowing down the damage to the cartilage and bone of the joints and improving your ability to do normal daily activities.

Ankylosing spondylitis Cosentyx is used to treat a condition called “ankylosing spondylitis”. The condition is an inflammatory disease primarily affecting the spine which causes inflammation of the spinal joints. If you have ankylosing spondylitis you will first be given other medicines. If you do not respond well enough to these medicines, you will be given Cosentyx to reduce the signs and symptoms of the disease, reduce inflammation and improve your physical function.

Cosentyx is used in adults with active ankylosing spondylitis.

Using Cosentyx in ankylosing spondylitis will benefit you by reducing the signs and symptoms of your disease and improving your physical function.

2. What you need to know before you use Cosentyx

Do not use Cosentyx:

 if you are allergic to secukinumab or any of the other ingredients of this medicine (listed in section 6).

If you think you may be allergic, ask your doctor for advice before using Cosentyx.

 if you have an active infection which your doctor thinks is important.

Warnings and precautions

Tell your doctor or pharmacist before using Cosentyx:

 if you currently have an infection  if you have long-term or repeated infections.

 if you have tuberculosis.

 if you have ever had an allergic reaction to latex.

 if you have Crohn’s disease.

 if you have recently had a vaccination or if you are due to have a vaccination during treatment with Cosentyx.

 if you are receiving any other treatment for psoriasis, such as another immunosuppressant or phototherapy with ultraviolet (UV) light.

Look out for infections and allergic reactions Cosentyx can potentially cause serious side effects, including infections and allergic reactions. You must look out for signs of these conditions while you are taking Cosentyx.

Stop using Cosentyx and tell your doctor or seek medical help immediately if you notice any signs indicating a possible serious infection or an allergic reaction. Such signs are listed under “Serious side effects” in section 4.





Children and adolescents Cosentyx is not recommended for children and adolescents (under 18 years of age) because it has not been studied in this age group.

Other medicines and Cosentyx

Tell your doctor or pharmacist:

 if you are taking, have recently taken or might take any other medicines.

 if you have recently had or are due to have a vaccination. You should not be given certain types of vaccines (live vaccines) while using Cosentyx.

Pregnancy, breast-feeding and fertility  It is preferable to avoid the use of Cosentyx in pregnancy. The effects of this medicine in pregnant women are not known. If you are a woman of childbearing potential, you are advised to avoid becoming pregnant and must use adequate contraception while using Cosentyx and for at least 20 weeks after the last Cosentyx dose. Talk to your doctor if you are pregnant, think you may be pregnant or are planning to have a baby.

 Talk to your doctor if you are breast-feeding or are planning to breast-feed. You and your doctor should decide if you will breast-feed or use Cosentyx. You should not do both. After using Cosentyx you should not breast-feed for at least 20 weeks after the last dose.

Driving and using machines Cosentyx has no or negligible influence on the ability to drive and use machines.

–  –  –

Always use this medicine exactly as your doctor has told you. Check with your doctor, nurse or pharmacist if you are not sure.

Cosentyx is given via injection under your skin (known as a subcutaneous injection). You and your doctor should decide if you should inject Cosentyx yourself.

It is important not to try to inject yourself until you have been trained by your doctor, nurse or pharmacist.

A caregiver may also give you your Cosentyx injection after proper training.

For detailed instructions on how to inject Cosentyx, see “Instructions for use of the Cosentyx SensoReady pen” at the end of this leaflet.

How much Cosentyx is given and for how long Your doctor will decide how much Cosentyx you need and for how long.

Plaque psoriasis  The recommended dose is 300 mg by subcutaneous injection.

 Each 300 mg dose is given as two injections of 150 mg.

After the first dose you will receive further weekly injections at Weeks 1, 2 and 3. From Week 4, you will receive monthly injections. At each timepoint you will receive a 300 mg dose given as two injections of 150 mg.

Psoriatic arthritis For psoriatic arthritis patients who also have moderate to severe plaque psoriasis or patients who did not

respond well to medicines called tumour necrosis factor (TNF) blockers:

 The recommended dose is 300 mg by subcutaneous injection.

 Each 300 mg dose is given as two injections of 150 mg.

After the first dose you will receive further weekly injections at Weeks 1, 2 and 3. From Week 4, you will receive monthly injections. At each timepoint you will receive a 300 mg dose given as two injections of 150 mg.

For other psoriatic arthritis patients:

 The recommended dose is 150 mg by subcutaneous injection.

After the first dose you will receive further weekly injections at Weeks 1, 2 and 3. From Week 4, you will receive monthly injections.

Ankylosing spondylitis  The recommended dose is 150 mg by subcutaneous injection.

After the first dose you will receive further weekly injections at Weeks 1, 2 and 3. From Week 4, you will receive monthly injections.

Cosentyx is for long-term treatment. Your doctor will regularly monitor your condition to check that the treatment is having the desired effect.

If you use more Cosentyx than you should If you have received more Cosentyx than you should or the dose has been administered sooner than according to your doctor’s prescription, inform your doctor.

If you forget to use Cosentyx If you have forgotten to inject a dose of Cosentyx, inject the next dose as soon as you remember. Then talk to your doctor to discuss when you should inject the next dose.

If you stop using Cosentyx It is not dangerous to stop using Cosentyx. However, if you stop, your psoriasis, psoriatic arthritis or ankylosing spondylitis symptoms may come back.

If you have any further questions on the use of this medicine, ask your doctor, pharmacist or nurse.

4. Possible side effects Like all medicines, this medicine can cause side effects, although not everybody gets them.

Serious side effects Stop using Cosentyx and tell your doctor or seek medical help immediately if you get any of the following

side effects:

Possible serious infection - the signs may include:

 fever, flu-like symptoms, night sweats  feeling tired or short of breath, cough which will not go away  warm, red and painful skin, or a painful skin rash with blisters  burning sensation when passing urine.

Serious allergic reaction - the signs may include:

 difficulty breathing or swallowing  low blood pressure, which can cause dizziness or light-headedness  swelling of the face, lips, tongue or throat  severe itching of the skin, with a red rash or raised bumps.

Your doctor will decide if and when you may restart the treatment.

Other side effects Most of the following side effects are mild to moderate. If any of these side effects becomes severe, tell your doctor, pharmacist or nurse.

Some side effects are very common (may affect more than 1 in 10 people):

 upper respiratory tract infections with symptoms such as sore throat and stuffy nose (nasopharyngitis, rhinitis)

–  –  –

Some side effects are uncommon (may affect up to 1 in 100 people):

 oral thrush (oral candidiasis)  signs of low levels of white blood cells, such as fever, sore throat or mouth ulcers due to infections (neutropenia)  athlete’s foot (tinea pedis)  infection of the external ear (otitis externa)  discharge from the eye with itching, redness and swelling (conjunctivitis)  itchy rash (urticaria)

Some side effects are rare (may affect up to 1 in 1,000 people):

 severe allergic reaction with shock (anaphylactic reaction) Reporting of side effects If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly (see below). By reporting side effects you can help provide more information on the safety of this medicine.

–  –  –

5. How to store Cosentyx Keep this medicine out of the sight and reach of children.

Do not use this medicine:

 after the expiry date which is stated on the outer box or the label on the pen after “EXP”.

 if the liquid contains easily visible particles, is cloudy or is distinctly brown.

Store the pen sealed in its box to protect from light. Store in the refrigerator between 2°C and 8°C. Do not freeze. Do not shake.

This medicine is for single use only. Ask your pharmacist how to dispose of medicines no longer required.

6. Contents of the pack and other information What Cosentyx contains

- The active substance is secukinumab. Each pre-filled pen contains 150 mg secukinumab.

- The other ingredients are trehalose dihydrate, L-histidine, L-histidine hydrochloride monohydrate, L-methionine, polysorbate 80 and water for injections.

What Cosentyx looks like and contents of the pack Cosentyx solution for injection is a clear liquid. Its colour may vary from colourless to slightly yellow. Do not use if the liquid contains easily visible particles, is cloudy or is distinctly brown. Cosentyx is available in unit packs containing 1 or 2 pre-filled pen(s) and in multipacks containing 6 (3 packs of 2) pre-filled pens. Not all pack sizes may be marketed.

Marketing Authorisation Holder Novartis Europharm Limited Frimley Business Park Camberley GU16 7SR United Kingdom Manufacturer Novartis Pharma GmbH Roonstraße 25 D-90429 Nuremberg Germany For any information about this medicine, please contact the local representative of the Marketing

Authorisation Holder:

–  –  –

This leaflet was last revised in 11/2015 Other sources of information

Detailed information on this medicine is available on the European Medicines Agency web site:

http://www.ema.europa.eu Instructions for use of the Cosentyx SensoReady pen

–  –  –

8. Check the green indicator fills the window:

 This means the medicine has been delivered. Contact your doctor if the green indicator is not visible.



Pages:   || 2 |


Similar works:

«WINTER 2012 Volume 5, Issue 4 Havanese Club of America HAVANESE HORIZONS Produced & Edited by: Getting Started with Our First Havanese J. Jonathan Sowa How did I get so involved with Havanese? It was the most natural thing in the world. My husInside This Issue band Clarke and I have had dogs all our lives. But after having health issues with our last few dogs, we HCA President’s Message wanted a better chance at having a healthy dog. The “My First Havanese” 1 Havanese Breed is so...»

«Bruce Rind, M.D. Background • Assistant Professor, Alternative and Complimentary Medicine, Howard University Medical School • Certified: Amer. Bd. of Holistic Medicine • Certified: Amer. Bd. of Anesthesiology Disclaimer The information provided here is for informational and educational purposes only. It is not intended as medical advice or for therapeutic purposes. Any discussion of therapy is intended only for purposes of illustration and example and not as a therapeutic guide for any...»

«Oxford UnitedHealthcare® Oxford Clinical Policy OBSTRUCTIVE SLEEP APNEA TREATMENT Policy Number: OUTPATIENT 020.32 T2 Effective Date: October 1, 2016 Table of Contents Page Related Policies INSTRUCTIONS FOR USE CONDITIONS OF COVERAGE BENEFIT CONSIDERATIONS COVERAGE RATIONALE DEFINITIONS APPLICABLE CODES  Orthognathic (Jaw) Surgery DESCRIPTION OF SERVICES CLINICAL EVIDENCE U.S. FOOD AND DRUG ADMINISTRATION REFERENCES POLICY HISTORY/REVISION INFORMATION. 25 INSTRUCTIONS FOR USE This Clinical...»

«Created by the Table de concertation jeunesse NDG (2010) Find the guide online at www.ndg.ca TABLE OF CONTENTS 1 – Sports & Recreation 8 – Gay LGBT 2 – Youth space 9 – Tutoring & Alternative schooling 3 – Youth employment 10 – Young parents 4 – Health & Mental health 11 – Bullying, gangs & Safety 5 – Shelter & Food 12 – Environment 6 – Drugs, Alcohol & Gambling 13 – Help lines 7 – Legal aid & Youth protection SPORTS & RECREATION www.ndg.ca NDG YOUTH INFO JEUNESSE NDG...»

«Cosmetics 2015, 2, 211-224; doi:10.3390/cosmetics2030211 OPEN ACCESS cosmetics ISSN 2079-9284 www.mdpi.com/journal/cosmetics Review Nanotechnology-Based Cosmetics for Hair Care Jamie Rosen 1, Angelo Landriscina 1 and Adam J. Friedman 2,3,* 1 Division of Dermatology, Department of Medicine, Albert Einstein College of Medicine, Bronx, NY 10467, USA; E-Mails: jrosen12@gmail.com (J.R.); angelo.landriscina@med.einstein.yu.edu (A.L.) 2 Department of Physiology and Biophysics, Albert Einstein College...»

«MINNETONKA INDEPENDENT SCHOOL DISTRICT #276 Service Center 5621 County Road 101 Minnetonka, Minnesota Minutes of June 15, 2006 School Board Meeting The Board of Education, Minnetonka Independent School District #276, met in regular session at 8:40 p.m. on Thursday, June 15, 2006 at the District Service Center, 5621 County Road 101, Minnetonka, Minnesota. Chairperson Adams presided. Other Board members present were: Pamela Langseth, Cal Litsey, Cathy Maes, Peggy Stefan, William Wenmark and...»

«The Tissue Response to Infectious Burden and Implantable Devices in Healthy and Diabetic Animal Models by Nga Le Brown Department of Biomedical Engineering Duke University Date:_Approved: _ Bruce Klitzman, Supervisor _ William “Monty” Reichert _ Fan Yuan _ Kam Leong _ Howard Levinson Dissertation submitted in partial fulfillment of the requirements for the degree of Doctor of Philosophy in the Department of Biomedical Engineering in the Graduate School of Duke University 2015 i v ABSTRACT...»

«25 January 2016 EMA/467700/2014 Human Medicines Evaluation Division Lessons learned from the review of the labelling of centrally authorised pandemic vaccines 1. Background The 2009 pandemic outbreak experience showed that due to the urgency of the situation and the logistical constraints that pharmaceutical companies faced to make vaccines available in a very short time, the review of the labelling (outer/immediate packaging) and the package leaflet was a challenging exercise. Applicants...»

«OFFICE OF THE STATE CORONER FINDINGS OF INQUEST CITATION: Inquest into the death of Leon Streader TITLE OF COURT: Coroner’s Court JURISDICTION: Brisbane FILE NO(s): COR 573/04(3) DELIVERED ON: 1 October 2009 DELIVERED AT: Brisbane HEARING DATE(s): 20 February 2007, 25 March, 22 April, 15 May and 20 June 2008 FINDINGS OF: Christine Clements, Deputy State Coroner CATCHWORDS: CORONERS: Inquest – Death in care, level 3 accredited accommodation, extreme heat conditions, medication and underlying...»

«KATHERINE A. AHRENS Kate.ahrens@hhs.gov EDUCATION 2012 Boston University Ph.D. in Epidemiology Dissertation title: Consequences of controlling viral infection during pregnancy: antiherpetic medication and influenza vaccination Dissertation committee chair: Martha Werler 2004 University of Michigan M.P.H. in Epidemiology 1999 Harvard University A.B. with honors in Biology RESEARCH POSITIONS 2016-present Health Scientist Office of the Assistant Secretary of Health Office of Population Affairs...»

«Diagnosing Pain Beyond Qì and Blood Stagnation A Look at Painful Obstruction (Bi Syndromes) Written The student clinic is a great place to get fresh perspectives as well as refine by: one’s thinking on almost any topic. Students never cease to amaze me with their beginner’s mind ingenious approaches to common problems. On Jason the other hand, I have noticed many common errors in thinking that happen Blalack across the board. Precisely because such ideas are so entrenched, they lend a good...»

«Product Information – Australia APO-ISOTRETINOIN CAPSULES NAME OF THE MEDICINE Chemical Name: (2Z, 4E, 6E, 8E)-3,7-dimethyl-9-(2,6,6-trimethylcyclohex-1-enyl)nona-2,4,6,8tetraenoic acid (also known as 13-cis-retinoic acid).Structural Formula: C20H2802 Molecular Formula: Molecular Weight: 300.44 CAS Registry Number: 4759-48-2 DESCRIPTION Isotretinoin is a yellow–orange to orange crystalline powder that is practically insoluble in water, soluble in methylene chloride, sparingly soluble in...»





 
<<  HOME   |    CONTACTS
2016 www.dissertation.xlibx.info - Dissertations, online materials

Materials of this site are available for review, all rights belong to their respective owners.
If you do not agree with the fact that your material is placed on this site, please, email us, we will within 1-2 business days delete him.